Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers


The solution


Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers.
We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.


News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Ricard Casanovas – Meet the Advisory Board!

We are continuing to introduce the remarkable individuals who make up Gate2Brain’s external advisory…

XVth SPLC-CRS Conference on Controlled Drug Delivery

Last week, Gate2Brain had the privilege of attending the XVth SPLC-CRS Conference on Controlled Drug…

International Childhood Cancer Day

San Joan de Déu Hospital - Family Assistance Program The daily routine of families with hospitalized…

Gate2Brain at Bio-Europe Spring

Gate2Brain will be attending BIO-Europe Spring partnering event on March 18-20, 2024. 📌Be sure to…

International Day of Women & Girls in Science

Women in STEAM at IRSJD "As many data indicate, currently women represent 50% of the research staff…

Gate2Brain part of the CDTI’s NEOTEC program

Gate2Brain Gate2Brain is a biotech company focused on the development of therapeutics that efficiently…

Gate2Brain: the startup that delivers drugs to the brain to treat childhood cancer with no cure

Gate2Brain developed with its technology three families of peptides, small proteins or 'tractors', capable…

Collaboration with the Instituto de Parasitología y Biomedicina López-Neyra (IPBLN)

We are pleased to announce that we have strengthened the collaboration that we have had for some time…

Gate2Brain at the i4KIDS I i4KIDS-EUROPE Pediatric Innovation Training Capsules

Gate2Brain will be participating together with Tully at the i4KIDS I i4KIDS-EUROPE Pediatric Innovation…

Making therapies a reality for patients by addressing unmet medical needs.


Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain